| |
|
|
| Saturday,
September 9 |
| |
| 10:00
am - 04:00 pm Live
Surgery |
| 05:00
pm - 07:00 pm Fluorescein
Angiography & Surgical Case Conference |
| 08:00
pm - 11:00 pm Welcome
Reception and Dinner |
|
|
|
Sunday,
September 10
|
| |
| 08:00 |
Opening
of continuing Film Projection |
| 08:00 |
Opening
Remarks Julia Haller, Didier Ducournau & Jean-Paul Amar
|
| |
| 08:05 |
Symposium
I: Anti-Angiogenesis (Part 1)
Presiding Officer: Susan B; Bressler Chair: Ursula Schmidt-Erfurth Moderator:
Tom S. Chang |
| |
| 08:05 |
Combined
efficacy of intravitreal ranibizumab in two Phase III studies of CNV
secondary to ARMD
Anat Loewenstein
|
| 08:12 |
Combined
Safety of Intravitreal Ranibizumab in Two Phase III Studies of CNV Secondary
to ARMD Paolo
Lanzetta |
| 08:19 |
Two-year
efficacy and safety results from the MARINA study
Ursula Schmidt-Erfurth |
| 08:26 |
Consistency
of effect of ranibizumab at 2 doses on contrast sensitivity in 3 Phase
III and IIIB studies of patients with CNV secondary to AMD
Jean-Francois Korobelnik |
| 08:33 |
Discussion
|
| 08:37 |
Intravitreal
Ranibizumab (LucentisTM) plus Verteporfin PDT for Neovascular ARMD: FOCUS
2-year Results
Andrew Antoszyk |
| 08:44 |
PIER:
Year 1 Results of a Phase IIIB Study of Ranibizumab Efficacy and Safety
in CNV Due to ARMD
Prema Abraham |
| 08:51 |
Pier:
Year 1 FA/OCT Results in a study of Ranibizumab (Lucentis™) for CNV Due
to ARMD William
F. Mieler |
| 08:58 |
An
OCT-Guided Variable-Dosing Regimen with Lucentis™ (Ranibizumab) in Neovascular
AMD: One Year Results from the PrONTO Study
Philip J. Rosenfeld |
| 09:05 |
Discussion
|
| 09:10 |
Introduction
of Featured Guest Lecture: Judah Folkman
Presiding Officers: Didier Ducournau, Julia Haller and Gene de Juan
|
| 09:15 |
Potential
Future Advances in Ophthalmology from Research in Tumor Angiogenesis
Judah Folkman, MD |
| 10:00 |
Discussion |
| 10:05 |
Poster
Session (AMD/ANTI-ANGIOGENESIS) |
| |
| 10:40 |
Symposium
II: Anti-Angiogenesis (Part 2) Presiding Officer: Lawrence
Singerman Chair: David Williams Moderators: Frank Koch |
| |
| 10:40 |
Open-label,
multicenter, Phase II Study Assessing the safety and efficacy of same-day
Verteporfin and liquid ranibizumab 0.5mg (PROTECT study)
Sebastian Wolf |
| 10:47 |
Ranibizumab
(Lucentis) Vision-Specific Quality of Life Trough 24 Months in Neovascular
ARMD Subjects in Marina: A Phase III Clinical Trial Tom
S. Chang |
| 10:54 |
Vision-Specific
Quality of Life at 12 Months in Predominantly Classic Neovascular ARMD
in Anchor: A Phase III Trial of Ranibizumab and Verteporfin PDT Neil
M. Bressler |
| 11:01 |
The
Value and Cost-Effectiveness of Interventions for Subfoveal Neovascular
ARMD Melissa
Brown |
| 11:08 |
Discussion |
| 11:12 |
Intravitreally
Injected Anti-VEGF Drugs Exert a Biological Effect in the Fellow Eye
Tongalp Tezel |
| 11:16 |
Pharmacokinetics
of Intravitreal Bevacizumab (Avastin)
Sophie J. Bakri |
| 11:20 |
Vitreous
Levels of Unbound Bevacizumab and Unbound Vascular Endothelial Growth
Factors in Two Human Subjects
Paul M. Beer |
| 11:24 |
Stability
of bevacizumab (Avastin) after withdrawal into a syringe and refrigeration
or freezing
Colin A. McCannel |
| 11:28 |
Discussion |
| 11:31 |
Intravitreal
Bevacizumab for the treatment of CNV secondary to Ocular Histoplasmosis
and Multifocal Choroiditis
Sundeep Dev |
| 11:36 |
Short-Term
Outcomes in over 500 Intravitreal Bevacizumab Treatments for Retinal or
CVD at the New York Eye & Ear Infirmary
Thomas O. Muldoon |
| 11:41 |
Intravitreal
Bevacizumab As Isolated First Line Therapy In Patients With New Untreated
CNV Membranes
Alay Banker |
| 11:46 |
Six-month
Follow up on 50 Consecutive Patients with Intravitreal Bevacizumab Injections
for Neovascular ARMD Samira
Khan |
| 11:51 |
Discussion |
| 11:55 |
Primary
Intravitreal Bevacizumab (Avastin) for the Treatment of CNV secondary
to ARMD: Results of the Pan-American Collaborative Retina Study Group
Jans Fromow-Guerra |
| 12:00 |
Intravitreal
Bevacizumab (Avastin) for the Treatment of Neovascular ARMD
Alessandro Castellarin |
| 12:05 |
Intravitreal
Bevacizumab (Avastin™) for Primary Treatment of Neovascular ARMD David
F. Williams |
| 12:10 |
Intravitreal
Bevacizumab (Avastin) Treatment of CNV Secondary to ARMD
Richard F. Spaide |
| 12:15 |
Discussion
|
| 12:18 |
Time
to recurrence of ARMD-related CNV leakage after a single initial intravitreous
injection bevacizumab (Avastin®): Implications for a retreatment Edgar
L. Thomas |
| 12:23 |
A
FA/ICG analysis of the retinal/choroidal vasculature and CNV membrane
complex six months following intravitreal Avastin injections
Paul E. Tornambe |
| 12:28 |
Intravitreal
Bevacizumab Compared with PDT for Juxtafoveal CNV Membranes in ARMD
Derek Barker |
| 12:33 |
Combination
therapy for wet ARMD using verteporfin PDT and intravitreal bevacizumab
Jose Dalma-Weiszhausz |
| 12:38 |
Discussion
|
| 12:41 |
Combined
PDT with Verteporfin and Intravitreal Bevacizumab for CNV in ARMD
Gaurav K. Shah |
| 12:46 |
Combined
PDT with Verteporfin and Intravitreal Bevacizumab for Subfoveal CNV in
ARMD David
Misch |
| 12:51 |
Combination
Avastin and Reduced Fluence PDT for CNV David
Callanan |
| 12:56 |
Intravitreal
Bevacizumab (Avastin) enhanced Pegaptanib (Macugen) therapy for CNV in
ARMD: An Avastin Booster
Michael J. Tolentino |
| 01:01 |
Vitrectomy
in Triple Therapy for CNV
Frank H.J. Koch |
| 01:06 |
Discussion
|
| 01:10 |
Young
Physicians Section' Lunch |
| |
Crystal
Apple Lecture: Controversies in the Management and Prevention of Endophthalmitis
Harry W. Flynn, MD |
| |
| 02:40 |
Symposium
III: Anti-Angiogenesis (Part 3) Presiding Officer: Paul
E. Tornambe Chair: Anthony Adamis Moderator: Albert Augustin |
| |
| 02:40 |
C.L.E.A.R.
- IT 1: A Phase I Safety, Tolerability, and Bioactivity Study of Intravitreal
VEGFTrap in Patients with Neovascular ARMD Quan
Dong Nguyen |
| 02:47 |
VEGF
small interfering (si) RNA, for Treatment of Wet ARMD
Lawrence J. Singerman |
| 02:54 |
The
Effects of Combined Inhibition of PDGF-B and VEGF-A Signaling in Murine
Models of Ocular Neovascularization
Anthony Adamis |
| 03:00 |
The
Role of a Selective VEGF Blockade in ARMD
Thomas R. Friberg |
| 03:06 |
Anecortave
Acetate Clinical Update
Peter K. Kaiser |
| 03:12 |
Discussion
|
| 03:16 |
Combined
IVT with PDT for the treatment of CNV in ARMD
Catherine Favard |
| 03:22 |
The
effect of Kenalog as adjunctive treatment to Visudyne in minimally classic
and occult neovascular ARMD: A prospective, randomized clinical trial
Tom Sheidow |
| 03:28 |
Six-month
Results of a Randomized, Double-Masked, Controlled Trial of IVT as an
Adjunct to PDT in Predominantly Classic Neovascular ARMD. The Canadian
RETINA Study
David Maberley |
| 03:34 |
Large
case series of different types of CNV after Combination Treatment (PDT
with intravitreal Triamcinolone)
Albert J. Augustin |
| 03:40 |
Discussion
|
| 03:45 |
AMD-panel
Moderator: Philip J. Rosenfeld |
| |
| Monday,
September 11 |
| |
| 08:00 |
Opening
of continuing Film Projection |
| |
08:00
|
Awards
& Special Presentations Presiding Officers: Julia Haller,
Gene de Juan, and George Williams |
| |
08:00
|
Introduction
of Pyron Award Winner
Brooks W. McCuen, II |
| 08:05 |
Pyron
Award Lecture: Evolving Concepts in Pharmacologic Vitreolysis
Brooks W. McCuen, II |
| 08:35 |
Introduction
of Founders Award Winner
Kirk H. Packo |
08:40
|
Founders
Award Lecture: Vitrectomy Technology - Where We've Been. Where We Are.
Where We Are Going. Kirk
H. Packo |
| 09:10 |
Pay
for Performance: A True Quality Initiative or a Means of Cost Control
William L. Rich, III |
| 09:20 |
American
Retina Foundation
Roy A. Levit |
| 09:25 |
Young
Phisicians Section's Crystal Apple Award Presentation |
| 09:27 |
PAT
Survey Award |
09:30
|
ASRS
Business Meeting |
10:00
|
Break/Exhibits/Poster
Session (IMAGING/SURGICAL DEVICES & INSTRUMENTATION/PHARMACOLOGY/SOCIOECONOMICS) |
| |
10:40
|
Symposium
IV: Imaging and AMD Presiding Officer: Giovanni Staurenghi
, Chair: Claude Boscher, Moderator: Gregg Kokame |
| |
| 10:40 |
Retinal
Measurements with 3D-OCT Alexander
C. Walsh |
10:45
|
SOCT
“Copernicus” a new diagnostic tool in retinology
Jerzy Nawrocki |
10:50
|
Active
CNV Without Subretinal or Intraretinal Fluid on OCT Imaging
G. Baker Hubbard |
10:55
|
Dualing
OCT Modalities: Contrasting Retinal Features Revealed by a Dual Mode High
Speed Ultrahigh Resolution Spectral and Temporal OCT/SLO Imager
Richard B. Rosen |
11:00
|
Spectral
Domain OCT Provides New Insight Into the Extent of Macular Pathology in
ARMD Cynthia
A. Toth |
11:05
|
Discussion
|
11:08
|
AMD,
hypertension and potential cardiovascular risks with intravitreal Avastin
injection Claude
Boscher |
11:13
|
Humanistic
Burden and Health Resource Utilization in Neovascular ARMD Patients from
Five Countries
Gisele Soubrane |
11:17
|
Comparison
of Comorbid Conditions Between Wet ARMD Patients and a Control Cohort
in the Medicare Population
Gergana Zlateva |
11:22
|
Myocardial
Infarction and Cerebrovascular Accident Rates in Patients with Neovascular
ARMD in a Healthcare Claims Database Emily
S. West |
| 11:27 |
Annual
Rates of Cardiovascular Events in Medicare Neovascular ARMD Patients
Tsontcho Ianchulev |
11:32
|
Discussion
|
11:36
|
Long
Term Results of the Age-Related Eye Disease Study
Emily Y. Chew |
11:41
|
Vitamin
Usage Patterns in the Prevention of Advanced ARMD in a Tertiary Care Population Susan B.
Bressler |
11:46
|
Discussion
|
11:51
|
Effect
of Initial Visual Acuity on Visual Loss in Untreated ARMD Eyes with Subfoveal
Neovascularization
Lucian Del Priore |
11:56
|
Incident
CNV Lesions in the Fellow Eyes of Participants with Unilateral Neovascular
ARMD during the Submacular Surgery
Trials Sharon D. Solomon |
| 12:01 |
Quantitative
OCT Sub-Analysis in Neovascular ARMD
SriniVas Sadda |
| 12:06 |
Treatment
of Retinal Angiomatous Proliferation Lesions Associated with Pigment Epithelial
Detachment with Focal Pulsed Laser Robert
P. Murphy |
| 12:11 |
Results
of a 1 Year Study of Feeder Vessel Therapy in ARMD
Giovanni Staurenghi |
| 12:15 |
Discussion
|
| 12:18 |
How
many days after onset is it too late to evacuate submacular hemorrhage
secondary to ARMD? Keye
L. Wong |
| 12:23 |
Pneumatic
displacement of submacular hemorrhage- a case series
Wilson Heriot |
| 12:28 |
Comparison
of Submacular Surgery and Natural History for the Treatment of Large Submacular
Hemorrhages from MD
John T. Thompson |
| 12:33 |
Recurrent
CNV after Macular Translocation Surgery With 360-degree Peripheral Retinectomy
Claxton A. Baer (Winner 2006 B&L Retina Fellows' Forum Research
Award) |
12:38
|
Subretinal
Surgery for Peripapillary Subretinal Neovascular Membranes
Gregg T. Kokame |
| 12:42 |
Discussion |
| 12:45 |
Prolonged
Choroidal Hypofluorescence following Verteporfin PDT Combined with Intravitreal
Triamcinolone Acetate Injection for Age-related CNVM Jeffrey
K. Luttrull |
| 12:50 |
Increased
Visual Acuity in Fellow Affected Eyes of Subjects Undergoing Therapy with
Intravenous EVIZON™ (Squalamine lactate) for Exudative ARMD
Michael Gast |
12:55
|
Two-year
Phase II/III Results (IMT002) of a Visual Prosthesis for Treatment of
Central Vision Loss due to End-Stage Macular Degeneration
Henry L. Hudson |
01:00
|
Discussion |
| |
02:10
|
Symposium
V: Surgical Devices and Instrumentation (Part 1) Presiding
Officer: Mike Trese, Chair: Tarek S. Hassan, Moderator: Claus Eckardt
|
| |
| 02:10 |
Evaluation
of the Artificial Silicon Retina™ Device for the Treatment of Vision Loss
from Retinitis Pigmentosa
John S. Pollack |
| 02:15 |
Chronic
retinal chip implant in blind patients with retinitis pigmentosa Gisbert
Richard |
| 02:20 |
Results
from a Chronically Implanted 16-Channel Epiretinal Prosthesis in Blind
Subjects Robert
J. Greenberg |
02:25
|
Discussion
|
| 02:28 |
Shedding
More Light on Endoillumination David
R. Chow |
02:33
|
Initial
Clinical Experience with a Patterned Scanning Laser (PASCAL) for the Treatment
of Retinal Diseases Julia
A. Haller |
| 02:38 |
Results
of Ophthalmic Surgical Training Using a High-fidelity Surgical Simulator
Coupled with a Curriculum Based on Task Breakdown and Analysis
Michael Grodin |
| 02:43 |
Cannulation
of the Suprachoroidal Space: Drug Delivery and Pharmacokinetics of Triamcinolone
Acetonide and Bevacizumab Timothy
W. Olsen |
| 02:48 |
Enzymatic
Alteration of Vitreous Cavity Oxygen Levels
Michael T. Trese |
| 02:53 |
Discussion
|
| 02:56 |
20
Gauge Sutureless Transconjunctival Vitrectomy Daniel
Polya |
| 03:01 |
Transconjunctival
20-G Sutureless Vitrectomy
Mikael Sebag |
| 03:06 |
Discussion
|
| 03:09 |
25
Gauge Vitrectomy: Outcomes and Complications
Carl Regillo |
| 03:14 |
Complications
of 25-gauge Vitrectomy Surgery
Robert A. Mittra |
| 03:19 |
A
Head-to-Head Intraoperative Clinical Comparison of Flow Rates: Electric
vs. Pneumatic 25-gauge High-Speed Vitreous Cutters
Tarek S. Hassan |
| 03:24 |
Discussion
|
| 03:27 |
23-Gauge
Vitrectomy as an effective and safe alternative for sutureless vitreous
surgery Keith
A. Warren |
| 03:31 |
23-Gauge
Vitrectomy in 100 Eyes: Short-Term Visual Outcomes and Complications
Harinderjit Singh |
| 03:35 |
Further
experience with 23-gauge transconjunctival vitrectomy
Claus Eckardt |
| 03:40 |
23g
Sutureless Vitrectomy: When and Why? Zoran
Tomic |
03:44
|
A
new 23 Gauge Vitrectomy System
George A. Williams |
| 03:49 |
New
Devices for Vitreoretinal Surgery
Carl C. Awh |
| 03:54 |
Discussion |
| 03:57 |
Surgical
Devices and Instrumentation Panel Discussion
Moderator: Carl C. Awh |
04:15
|
EVRS
Business Meeting |
07:20
|
Coach
transportation to Palm Beach Casino |
| 07:30 |
Casablanca
Night at Palm Beach Casino |
| |
| Tuesday,
September 12 |
| |
| 08:00 |
Opening
of continuing Film Projection |
| |
| 08:00 |
Symposium
VI: Surgical Devices and Instrumentation (Part 2) Presiding
Officer: Suber Huang, Chair: Steve Charles, Moderator: Oswaldo Brasil,
Sr. |
| |
| 08:00 |
Comparison
Of Wound Leakage Between Straight And Tunnel Scleral Incisions After 25
Gauge Vitrectomy
Luiz Hagemann |
| 08:05 |
The
integrity of wound closure after 23 versus 25 gauge sutureless vitrectomy
Oswaldo Moura Brasil, Jr. |
| 08:10 |
Unfavorable
Surgical Events in 25 vs. 20 Gauge Vitreous Surgery Saad
A. Shaikh |
| 08:15 |
Comparison
of visual recovery time in patients undergoing 20g and 25 gauge vitreous
surgery Suber
S. Huang |
| 08:20 |
Discussion |
| 08:25 |
Vitreous
Dynamics: The New Solid Development Concept. Vitreous Flow Analysis in
20, 23 and 25 Gauge Cutters
Octaviano Magalhaes |
| 08:30 |
Fluid
dynamics among different 25-gauge systems: principles for use in vitreoretinal
surgery Michel
E. Farah |
| 08:35 |
Improved
understanding of TSV-25g Vitrectomy system: Qualitative High Speed Video
Analysis Of Vitreous Movement Around Aperture of Vitreous Cutters
Mark S. Humayun |
| 08:40 |
Interface
Vitrectomy Steve
T. Charles |
| 08:45 |
Passive
Removal of Silicone Oil with 25-Gauge Transconjunctival Sutureless Vitrectomy
Instruments
Ziya Kapran |
| 08:50 |
Discussion |
| |
| 08:55 |
